Pharmaceutical

Merck and AstraZeneca receive approval for Lynparza in Japan

Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to treat BRCA-mutated (BRCAm) castration-resistant prostate cancer.

Aug 26, 2023 - 20:00
Merck and AstraZeneca receive approval for Lynparza in Japan
Merck (MSD) and AstraZeneca have received approval in Japan for Lynparza to treat BRCA-mutated (BRCAm) castration-resistant prostate cancer.
Read the original article

Tags:

Previous Article

Five ways to build trust in patient data sharing

Next Article

FDA Panel’s Divided Verdict Delays Approval for Medtronic’s Blood Pressure Device

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Wyden decries ‘astonishingly low’ tax rates for pharma companies as he probes business maneuvers

STAT+: Wyden decries ‘astonishingly low’ tax rates for ...

May 11, 2023

‘All of Us’ reports half of the genomes it has sequenced are from non-Europeans

‘All of Us’ reports half of the genomes it has sequence...

Feb 19, 2024

Developing high-potent APIs: The necessary steps to follow

Developing high-potent APIs: The necessary steps to follow

Aug 7, 2024